Ocular iontophoretic device and method for inhibiting vascular endothelial growth factor (VEGF) using the same

• US 6,579,276 B2
• Filed: 01/22/2001
• Issued: 06/17/2003
• Est. Priority Date: 01/22/2001
• Status: Expired due to Fees

• Current Assignee: Encore Medical Asset Corporation (Enovis Corp.)
• Original Assignee: Iomed, Inc. (Enovis Corp.)
• Inventors: Parkinson, Thomas M., Lloyd, Lindsay B., Szlek, Malgorzata
• Primary Examiner(s): Casler, Brian L.
• Assistant Examiner(s): Thanh, LoAn H.
• Application Number:
  US09/767,032
• Publication Number:
  US 20020099358A1
• Time in Patent Office: 876 Days
• Field of Search: 604/20, 604/890.1, 604/500-501, 604/521, 604/289-290, 604/294, 424/422, 424/424-425, 424/427
• US Class Current: 604/521
• CPC Class Codes: A61F 9/0008 Introducing ophthalmic products into the ocular cavity or retaining products therein putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00
• CPC Class Codes: A61N 1/30 Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis

Abstract

An ocular iontophoretic device for delivering an aptamer to an affected area of a living being'"'"'s eye for inhibiting VEGF function therein, the device comprising an active electrode assembly associated with a matrix and/or reservoir, wherein the matrix and/or reservoir includes an aptamer capable of inhibiting VEGF function.

A method for treating an affected area of a living being'"'"'s eye, comprising the steps of: associating an aptamer with an ocular iontophoretic device; positioning at least a portion of an ocular iontophoretic device on the eye of the living being; and iontophoretically delivering the aptamer to an affected area of the living being'"'"'s eye.

Claims

1. A method for treating an affected area of a living being'"'"'s eye, comprising the steps of:

associating an aptamer present in a concentration between approximately 0.1 mg and approximately 10 mg of aptamer per ml of water with an ocular iontophoretic device, wherein the water is buffered to a pH ranging between approximately 6.5 and approximately 8.5;

positioning at least a portion of the ocular iontophoretic device on the eye of a living being; and

iontophoretically delivering the aptamer to an affected area of the living being'"'"'s eye.

2. The method according to claim 1, wherein the step of associating the aptamer includes the step of associating an aptamer capable of inhibiting VEGF function.

3. The method according to claim 1, wherein the step of associating the aptamer includes the step of associating an aptamer capable of inhibiting at least one VEGF selected from the group consisting of VEGF-121, VEGF-165, VEGF-189, and VEGF-206.

4. The method according to claim 1, wherein the step of associating the aptamer includes the step of associating an aptamer capable of inhibiting VEGF-165.

5. The method according to claim 1, wherein the step of iontophoretically delivering the aptamer, includes the step of iontophoretically delivering the aptamer to at least one of the group consisting of the vitreous humor, retina, choroid, circulation of the retina, circulation of the choroid, and sclera.

6. The method according to claim 1, wherein the step of iontophoretically delivering the aptamer, includes the step of iontophoretically loading a sclera of the living being'"'"'s eye with the aptamer for prolonged delivery into back regions of the living being'"'"'s eye.

7. The method according to claim 1, wherein the step of iontophoretically delivering the aptamer, includes the step of iontophoretically delivering the aptamer at a current between approximately 0.1 mA and approximately 4 mA for a period of between approximately 1 and approximately 60 minutes.

8. The method according to claim 1, wherein the step of iontophoretically delivering the aptamer, includes the step of delivering the aptamer using negative polarity electrical current.

9. The method according to claim 1, wherein the step of positioning at least a portion of the ocular iontophoretic device on the eye of a living being includes the step of applying at least a portion of the ocular iontophoretic device to a conjunctival surface in a region of a pars planum.

10. A method for treating an affected area of a living being'"'"'s eye, comprising the steps of:

associating an aptamer with an ocular iontophoretic device;

associating a PEGylating agent with the aptamer

positioning at least a portion of the ocular iontophoretic device on the eye of a living being; and

iontophoretically delivering the aptamer to an affected area of the living being'"'"'s eye.

11. The method according to claim 10, wherein the step of associating a PEGylating agent includes the step of associating a PEGylating agent comprising a moiety selected from the group consisting of isocyanates, amino groups, and mixtures thereof.

12. A method for inhibiting VEGF function within an affected area of a living being'"'"'s eye, comprising the steps of:

associating an aptamer present in a concentration between approximately 0.1 mg and approximately 10 mg of aptamer per ml of water with a matrix of an ocular iontophoretic device, wherein the water is buffered to a pH ranging between approximately 6.5 and approximately 8.5;

associating the ocular iontophoretic device having an active electrode assembly with the eye of the living being;

iontophorectically delivering an effective amount of the aptamer to an affected area of the living being'"'"'s eye having an amount of VEGF;

binding the effective amount of aptamer to the amount of VEGF; and

inhibiting function of the amount of VEGF.

13. The method according to claim 12, wherein the step of associating the aptamer includes the step of associating an aptamer capable of inhibiting VEGF function.

14. The method according to claim 12, wherein the step of associating the aptamer includes the step of associating an aptamer capable of inhibiting at least one VEGF selected from the group consisting of VEGF-121, VEGF-165, VEGF-189, and VEGF-206.

15. The method according to claim 12, wherein the step of associating the aptamer includes the step of associating an aptamer capable of inhibiting VEGF-165.

16. The method according to claim 12, wherein the step of iontophoretically delivering the aptamer, includes the step of iontophoretically delivering the aptamer to at least one of the group consisting of the vitreous humor, retina, choroid, circulation of the retina, circulation of the choroid, and sclera.

17. The method according to claim 12, wherein the step of iontophoretically delivering the aptamer, includes the step of iontophoretically loading a sclera of the living being'"'"'s eye with an effective amount of the aptamer for prolonged delivery into back regions of the living being'"'"'s eye.

18. The method according to claim 12, wherein the step of iontophoretically delivering the aptamer, includes the step of iontophoretically delivering an effective amount of the aptamer at a current between approximately 0.1 mA and approximately 4 mA for a period of between approximately 1 and approximately 60 minutes.

19. The method according to claim 12, wherein the step of iontophoretically delivering the aptamer, includes the step of delivering the aptamer using negative polarity electrical current.

20. The method according to claim 12, wherein the step of associating the ocular iontophoretic device having an active electrode assembly with the eye of the living being includes the step of applying at least a portion of the ocular iontophoretic device to a conjunctival surface in a region of a pars planum.

21. A method for inhibiting VEGF function within an affected area of a living being'"'"'s eye, comprising the steps of:

associating an aptamer with a matrix of an ocular iontophoretic device;

associating a PEGylating agent with the aptamer;

associating the ocular iontophoretic device having an active electrode assembly with the eye of the living being;

iontophorectically delivering an effective amount of the aptamer to an affected area of the living being'"'"'s eye having an amount of VEGF;

binding the effective amount of aptamer to the amount of VEGF; and

inhibiting function of the amount of VEGF.

22. The method according to claim 21, wherein the step of associating a PEGylating agent includes the step of associating a PEGylating agent comprising a moiety selected from the group consisting of isocyanates, amino groups, and mixtures thereof.